TMAO reduces bile acid pools, inhibiting FXR activity, disrupting bile acid-FXR signaling, and upregulating pathways worsening hepatic steatosis, as confirmed in HFD-fed C57BL/6J mice and human samples (154). The gene discussed is NR1H4; the disease is fatty liver disease.